5.37
-0.01 (-0.19%)
| Previous Close | 5.38 |
| Open | 5.36 |
| Volume | 1,185,453 |
| Avg. Volume (3M) | 8,924,157 |
| Market Cap | 419,159,648 |
| Price / Book | 1.47 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 7.95 |
| Operating Cash Flow (TTM) | -192.25 M |
| Levered Free Cash Flow (TTM) | -110.31 M |
| Return on Assets (TTM) | -31.26% |
| Return on Equity (TTM) | -62.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Replimune Group, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.25 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.51% |
| % Held by Institutions | 107.50% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Boxer Capital Management, Llc | 30 Jun 2025 | 2,211,341 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (HC Wainwright & Co., 309.68%) | Buy |
| Median | 4.00 (-25.51%) | |
| Low | 2.00 (BMO Capital, -62.76%) | Sell |
| Average | 7.00 (30.35%) | |
| Total | 2 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 3.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 23 Jul 2025 | 2.00 (-62.76%) | Sell | 3.34 |
| Barclays | 23 Jul 2025 | 3.00 (-44.13%) | Hold | 3.34 |
| JP Morgan | 22 Jul 2025 | 9.00 (67.60%) | Hold | 2.81 |
| 16 Jul 2025 | 19.00 (253.82%) | Buy | 12.63 | |
| Jefferies | 22 Jul 2025 | 6.00 (11.73%) | Buy | 2.81 |
| Leerink Partners | 22 Jul 2025 | 3.00 (-44.13%) | Hold | 2.81 |
| Wedbush | 22 Jul 2025 | 4.00 (-25.51%) | Hold | 2.81 |
| HC Wainwright & Co. | 03 Jul 2025 | 22.00 (309.68%) | Buy | 9.40 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Sep 2025 | Announcement | Shareholders SueWallSt in New Class Action Against Replimune Group, Inc. - Act Now |
| 02 Sep 2025 | Announcement | Replimune Announces Type A Meeting Scheduled with FDA |
| 27 Aug 2025 | Announcement | Shareholders SueWallSt in New Class Action Against Replimune Group, Inc. - Act Now |
| 26 Aug 2025 | Announcement | Shareholders SueWallSt in New Class Action Against Replimune Group, Inc. - Act Now |
| 20 Aug 2025 | Announcement | Investors SueWallSt as Replimune Group, Inc. Faces Securities Fraud Allegations |
| 07 Aug 2025 | Announcement | Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update |
| 22 Jul 2025 | Announcement | Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma |
| 11 Jul 2025 | Announcement | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |